Calf Augmentation in Kansas
Calf Augmentation in Kansas section, includes general infrmation about Calf Augmentation Procedure, Calf Augmentation Kansas Local News, Calf Augmentation Kansas Surgeon Locator and other Calf Augmentation related material.
Calf Augmentation Procedure
This procedure offers a solution for those people that have underdeveloped calves or wish to augment them. The idea is to shape and size the calves by surgical insertion of implants. The implants are made of soft silicon and they come in different shapes and sizes. Before the operation your legs will be measured to select a proper implant for your needs. There is an alternative to implants. Calf augmentation can also be performed by liposuction of fat from other body parts and injecting it into the calves. This method is not suitable for people with no extra fat to be removed. Another problem is fat absorption that eventually occurs, sometimes creating not symmetric calves. Men and women can benefit from this procedure. Men usually want to increase the muscle bulk, giving them more masculine look and women wish to get more symmetrical appearance of their legs. This procedure also may help to correct some congenital defects, those include polio, spina bifida and clubfoot, all this conditions may be associated with undeveloped calves.
This procedure can be done with local or general anesthesia, and it usually lasts for an hour. During the operation the patient is laying on their back. A cut is made in the concavity behind the knee, then the skin is gently separated and a space is created. The implant is inserted above the muscles. After one leg is done the doctor performs the same on the other one. After the symmetry is confirmed the surgeon closes the cuts with stitches.
Every operation has its ricks. This one includes bleeding, infection and sometimes implants shrinkage and asymmetry.
After the surgery you may feel some degree of pain. Your doctor'll subscribe you for painkillers. At the first two days you'll be asked to raise your legs whenever you are sitting, this to reduce swelling. Afterwards, the bandages are removed and you are encouraged to walk more intensively to train your calve muscles. For about two weeks you'll fell like you're calves is been through excessive workout. Swelling and bruising also may appear, they are only temporary and will improve with time. You'll be able to go back to work after 7-10 days. You'll get detailed instructions from you're surgeon regarding the activities you should avoid, for example long walking, weight lifting and running. Usually, most of the patients are able to return to their daily activities after 4-6 weeks.
Other Calf Augmentation Procedures
All Body Procedures
Calf Augmentation Kansas (current)
Calf Augmentation Kansas Buttock Augmentation
Calf Augmentation Kansas Bariatric surgery
Calf Augmentation Kansas Liposuction
Calf Augmentation Kansas Body Contouring
More Kansas info...
Kansas Understand Although native Americans have lived in Kansas for thousands of years and the first Europeans visited in the 1600s, most Kansas communities date from the early to mid 1880s. The real development of Kansas didn’t take place until the 1850s when proslavery settlers from Missouri and antislavery settlers from New England flooded into the area. This period of "Bleeding Kansas" included a great deal of violence and some people consider this area to have been the cradle of the Civil War. In communities like Lawrence, Kansas many organizations and businesses still proudly display the "free state" name.
Kansas Get around The only way to travel in Kansas is to drive. It's part of the experience of being in the state to spend time on the road. Take the time to plan a route off of the main highways and see the country.
Plastic Surgery News...
- M's Science Corporation (MSC), a clinical stage discovery and development company announced that it initiated a Phase 2 study in Europe with its lead product SA4503 for treatment of stroke. Earlier this year, MSC announced the initiation of a Phase 2 trial with SA4503 for the treatment of major depression.
- A report on 5 years treatment with infliximab in patients with ankylosing spondylitis (AS) has been published in the Annals of the Rheumatic Diseases. These patients had initially been treated with infliximab in a 12-week, double-blind, placebo-controlled study (n=69) and at week 12, patients initially assigned to placebo switched to infliximab. Clinical efficacy was maintained in several open-label extension phases of this study in which patients were treated continuously with infliximab infusions of 5 mg/kg every 6 weeks for up to 3 years (FU1). After a short phase of discontinuation and restart of infliximab therapy because of clinical relapse, patients received continuous treatment. The primary outcome of this extension was remission according to the ASsessment in Ankylosing Spondylitis (ASAS) criteria at the end of year 5 of the study (FU2). Of the 43 patients who completed year 3, 42 agreed to continue, 38 of which (90.5%) finished year 5 (55% of 69 initially). The following findings were reported:
• Partial clinical remission was achieved in 13 of 38 patients (34.2%) at FU1 and FU2.
• At FU2, the mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was 2.5 (baseline: 6.4, FU1:2.5).
• BASDAI values < 4 were seen in 79% of patients at both, FU1 and FU2.
• ASAS 20% and 40% responses were seen in 32 (84%) and 24 (63%) patients at FU2, respectively.
• During the fourth and fifth year of the study, 36 of 38 patients (94.7%) reported at least one adverse event; the most frequently reported events were common cold (41%), bronchitis (11%) and increase of liver enzymes (6.5%).
• Six of the 43 patients (14%) at FU1 reported serious adverse events (SAE) during years 4 and 5 of the study: 1 patient withdrew because of recurrent vaginal infections and the other patient due to repeated infections of the upper respiratory tract.
The researchers conclude “this study shows that therapy of AS patients is efficacious and safe over 5 years of almost continuous treatment. There was no indication of loss of response as indicated by the persistent rate of remission and low disease activity. As we had tried to discontinue therapy after 3 years without success we believe that continuous therapy is necessary to achieve a lasting effect in these patients.”